Logo image of RGLS

REGULUS THERAPEUTICS INC (RGLS) Stock Fundamental Analysis

NASDAQ:RGLS - Nasdaq - US75915K3095 - Common Stock - Currency: USD

1  +0.03 (+3.09%)

After market: 1.04 +0.04 (+4%)

Fundamental Rating

3

Taking everything into account, RGLS scores 3 out of 10 in our fundamental rating. RGLS was compared to 572 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for RGLS as it has an excellent financial health rating, but there are worries on the profitability. RGLS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year RGLS has reported negative net income.
RGLS had a negative operating cash flow in the past year.
RGLS had negative earnings in each of the past 5 years.
In the past 5 years RGLS always reported negative operating cash flow.
RGLS Yearly Net Income VS EBIT VS OCF VS FCFRGLS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M

1.2 Ratios

RGLS has a Return On Assets (-44.40%) which is comparable to the rest of the industry.
RGLS has a better Return On Equity (-47.96%) than 67.08% of its industry peers.
Industry RankSector Rank
ROA -44.4%
ROE -47.96%
ROIC N/A
ROA(3y)-66.31%
ROA(5y)-56.98%
ROE(3y)-92.46%
ROE(5y)-86.17%
ROIC(3y)N/A
ROIC(5y)N/A
RGLS Yearly ROA, ROE, ROICRGLS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K

1.3 Margins

RGLS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RGLS Yearly Profit, Operating, Gross MarginsRGLS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20K -40K -60K -80K -100K

More info and screens

7

2. Health

2.1 Basic Checks

RGLS has more shares outstanding than it did 1 year ago.
RGLS has more shares outstanding than it did 5 years ago.
RGLS has a better debt/assets ratio than last year.
RGLS Yearly Shares OutstandingRGLS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M
RGLS Yearly Total Debt VS Total AssetsRGLS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M

2.2 Solvency

Based on the Altman-Z score of -3.16, we must say that RGLS is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -3.16, RGLS perfoms like the industry average, outperforming 46.73% of the companies in the same industry.
There is no outstanding debt for RGLS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.16
ROIC/WACCN/A
WACCN/A
RGLS Yearly LT Debt VS Equity VS FCFRGLS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 14.14 indicates that RGLS has no problem at all paying its short term obligations.
RGLS has a Current ratio of 14.14. This is amongst the best in the industry. RGLS outperforms 88.14% of its industry peers.
A Quick Ratio of 14.14 indicates that RGLS has no problem at all paying its short term obligations.
RGLS's Quick ratio of 14.14 is amongst the best of the industry. RGLS outperforms 88.14% of its industry peers.
Industry RankSector Rank
Current Ratio 14.14
Quick Ratio 14.14
RGLS Yearly Current Assets VS Current LiabilitesRGLS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

RGLS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 32.70%, which is quite impressive.
EPS 1Y (TTM)32.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, RGLS will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.18% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y45.36%
EPS Next 2Y9.8%
EPS Next 3Y0.4%
EPS Next 5Y19.18%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RGLS Yearly Revenue VS EstimatesRGLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M 1B
RGLS Yearly EPS VS EstimatesRGLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -50 -100 -150

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RGLS. In the last year negative earnings were reported.
Also next year RGLS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RGLS Price Earnings VS Forward Price EarningsRGLS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RGLS Per share dataRGLS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.8%
EPS Next 3Y0.4%

More info and screens

0

5. Dividend

5.1 Amount

RGLS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

REGULUS THERAPEUTICS INC

NASDAQ:RGLS (1/30/2025, 8:00:01 PM)

After market: 1.04 +0.04 (+4%)

1

+0.03 (+3.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)N/A N/A
Inst Owners95.49%
Inst Owner Change-0.01%
Ins Owners1.69%
Ins Owner Change1.08%
Market Cap65.50M
Analysts83.33
Price Target10.54 (954%)
Short Float %2.63%
Short Ratio5.29
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-17.37%
Min EPS beat(2)-21.11%
Max EPS beat(2)-13.63%
EPS beat(4)1
Avg EPS beat(4)-15.45%
Min EPS beat(4)-27.78%
Max EPS beat(4)0.72%
EPS beat(8)5
Avg EPS beat(8)-2.54%
EPS beat(12)6
Avg EPS beat(12)-1.36%
EPS beat(16)9
Avg EPS beat(16)3.19%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-52.17%
EPS NY rev (1m)0%
EPS NY rev (3m)-12.8%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.75
P/tB 0.75
EV/EBITDA N/A
EPS(TTM)-1.07
EYN/A
EPS(NY)-1.26
Fwd EYN/A
FCF(TTM)-0.56
FCFYN/A
OCF(TTM)-0.55
OCFYN/A
SpS0
BVpS1.33
TBVpS1.32
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -44.4%
ROE -47.96%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-66.31%
ROA(5y)-56.98%
ROE(3y)-92.46%
ROE(5y)-86.17%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 122.32%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.14
Quick Ratio 14.14
Altman-Z -3.16
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)208.13%
Cap/Depr(5y)129.61%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.5%
EPS Next Y45.36%
EPS Next 2Y9.8%
EPS Next 3Y0.4%
EPS Next 5Y19.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-49.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-61.23%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-32.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-32.67%
OCF growth 3YN/A
OCF growth 5YN/A